A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available

Michelle Gooey; Evelyn Wong; Alisa Pedrana; Nicole Allard; Joseph Doyle; Margaret Hellard; Amanda Wade

doi:10.1071/SH19189

A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available

Michelle Gooey, Evelyn Wong, Alisa Pedrana, Nicole Allard, Joseph Doyle, Margaret Hellard, Amanda Wade

Research output: Contribution to journal › Article › Research › peer-review

Abstract

In 2016, hepatitis C direct-acting antivirals (DAAs) became available in Australia. A group of general practitioners (GPS) were surveyed twice to assess hepatitis C knowledge and management 191/1000 (19.1%) responded at baseline, 164/938 (17.5%) at follow up. Participants' mean Knowledge score increased: Baseline 5.75 (95% CI 5.61-5.91), follow up 6.09 (95% CI 5.95-6.22 P <0.01). At follow up, 36/163 (22%) had prescribed DAAs compared with 23/187 (12%) at baseline (χ2(1) = 5.95, P = 0.02) however, 67/150 (45%) were unsure of treatment eligibility for people who inject drugs. Additional support for GPS is warranted to ensure optimal hepatitis C management in primary care.

Original language	English
Pages (from-to)	387–389
Number of pages	3
Journal	Sexual Health
Volume	17
Issue number	4
DOIs	https://doi.org/10.1071/SH19189
Publication status	Published - 2020

Keywords

general practice
primary care

Access to Document

10.1071/SH19189

Link to publication in Scopus

Cite this

@article{603dae4bd4c04d4eb8e0439e4a56bfb4,

title = "A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available",

abstract = "In 2016, hepatitis C direct-acting antivirals (DAAs) became available in Australia. A group of general practitioners (GPS) were surveyed twice to assess hepatitis C knowledge and management 191/1000 (19.1%) responded at baseline, 164/938 (17.5%) at follow up. Participants' mean Knowledge score increased: Baseline 5.75 (95% CI 5.61-5.91), follow up 6.09 (95% CI 5.95-6.22 P <0.01). At follow up, 36/163 (22%) had prescribed DAAs compared with 23/187 (12%) at baseline (χ2(1) = 5.95, P = 0.02) however, 67/150 (45%) were unsure of treatment eligibility for people who inject drugs. Additional support for GPS is warranted to ensure optimal hepatitis C management in primary care. ",

keywords = "general practice, primary care",

author = "Michelle Gooey and Evelyn Wong and Alisa Pedrana and Nicole Allard and Joseph Doyle and Margaret Hellard and Amanda Wade",

year = "2020",

doi = "10.1071/SH19189",

language = "English",

volume = "17",

pages = "387–389",

journal = "Sexual Health",

issn = "1448-5028",

publisher = "CSIRO",

number = "4",

}

A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available. / Gooey, Michelle; Wong, Evelyn; Pedrana, Alisa; Allard, Nicole; Doyle, Joseph; Hellard, Margaret; Wade, Amanda.

In: Sexual Health, Vol. 17, No. 4, 2020, p. 387–389.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available

AU - Gooey, Michelle

AU - Wong, Evelyn

AU - Pedrana, Alisa

AU - Allard, Nicole

AU - Doyle, Joseph

AU - Hellard, Margaret

AU - Wade, Amanda

PY - 2020

Y1 - 2020

N2 - In 2016, hepatitis C direct-acting antivirals (DAAs) became available in Australia. A group of general practitioners (GPS) were surveyed twice to assess hepatitis C knowledge and management 191/1000 (19.1%) responded at baseline, 164/938 (17.5%) at follow up. Participants' mean Knowledge score increased: Baseline 5.75 (95% CI 5.61-5.91), follow up 6.09 (95% CI 5.95-6.22 P <0.01). At follow up, 36/163 (22%) had prescribed DAAs compared with 23/187 (12%) at baseline (χ2(1) = 5.95, P = 0.02) however, 67/150 (45%) were unsure of treatment eligibility for people who inject drugs. Additional support for GPS is warranted to ensure optimal hepatitis C management in primary care.

AB - In 2016, hepatitis C direct-acting antivirals (DAAs) became available in Australia. A group of general practitioners (GPS) were surveyed twice to assess hepatitis C knowledge and management 191/1000 (19.1%) responded at baseline, 164/938 (17.5%) at follow up. Participants' mean Knowledge score increased: Baseline 5.75 (95% CI 5.61-5.91), follow up 6.09 (95% CI 5.95-6.22 P <0.01). At follow up, 36/163 (22%) had prescribed DAAs compared with 23/187 (12%) at baseline (χ2(1) = 5.95, P = 0.02) however, 67/150 (45%) were unsure of treatment eligibility for people who inject drugs. Additional support for GPS is warranted to ensure optimal hepatitis C management in primary care.

KW - general practice

KW - primary care

UR - http://www.scopus.com/inward/record.url?scp=85090052100&partnerID=8YFLogxK

U2 - 10.1071/SH19189

DO - 10.1071/SH19189

M3 - Article

C2 - 32693908

AN - SCOPUS:85090052100

VL - 17

SP - 387

EP - 389

JO - Sexual Health

JF - Sexual Health

SN - 1448-5028

IS - 4

ER -